First humans test new shot to stop a major form of malaria
NCT ID NCT07172724
Summary
This is the first study in people to test a new vaccine called Vivaxin, designed to prevent malaria caused by the Plasmodium vivax parasite. The main goal is to check if the vaccine is safe and causes an immune response in 48 healthy adults who have never had malaria. Participants will receive three shots over two months and be closely monitored for side effects for a full year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA VIVAX are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centro de Pesquisas Clínicas (CPC) do Hospital das Clínicas (HC) da UFMG/ Filial Ebserh
Belo Horizonte, Minas Gerais, 30130-100, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.